This Article  • Full text  • PDF  • Incomplete Financial Disclosure  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Related letter  • Similar articles in JAMA  Topic Collections  • Pediatrics  • Neonatology and Infant Care  • Diagnosis  • Genetics  • Genetic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Randi J. Hagerman, MD; Paul J. Hagerman, MD, PhD

JAMA. 2008;300(20):2419-2421.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Mutations of a single gene, fragile X mental retardation 1 (FMR1), give rise to a family of disorders occurring throughout the entire life span, including the most common heritable form of intellectual disability, fragile X syndrome, and premature menopause (primary ovarian insufficiency). Moreover, mutations of FMR1 are the cause of one of the most common single-gene, late-onset neurodegenerative disorders, fragile X–associated tremor/ataxia syndrome (FXTAS). Some clinicians might assume they will rarely if ever encounter one of these disorders; that assumption would be both false and unwise.

Because of the risks associated with these disorders, newborn screening is being considered. The recent development of an accurate and inexpensive blood spot screening test capable of identifying both premutation and full mutation alleles¹ is facilitating at least 2 large-scale newborn screening studies to move forward in the United States. Newborn screening for . . . [Full Text of this Article]

Author Affiliations: M.I.N.D. Institute (Dr R. Hagerman), and Departments of Pediatrics (Dr R. Hagerman) and Biochemistry and Molecular Medicine (Dr P. Hagerman), School of Medicine, University of California, Davis.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTER

Incomplete Financial Disclosure in a Commentary on Testing for Fragile X Gene Mutations Throughout the Life Span
Paul J. Hagerman
JAMA. 2009;301(6):601-602.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Incomplete Financial Disclosure in a Commentary on Testing for Fragile X Gene Mutations Throughout the Life Span
Hagerman
JAMA 2009;301:601-602.
FULL TEXT